Physician profile
Roy E Kuhl
NPI 1992882021
$1,096.36
in general payments reported to CMS, 2019-2025
16 companies · $410 in 2025
The $410 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.28 · 2020: $84.57 · 2021: $18.92 · 2022: $62.67 · 2023: $99.52 · 2024: $384 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $893.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $275.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $170.58 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $168.85 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $91.96 | 2022-2025 | Mounjaro, Zepbound |
| Amgen INC. | $66.56 | 2022-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $57.79 | 2024-2025 | |
| Abbvie INC. | $47.62 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.43 | 2024-2025 | Trintellix |
| Xeris Pharmaceuticals, INC. | $36.99 | 2024-2025 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $32.74 | 2024 | Xarelto |
| Genentech USA, INC. | $20.89 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.94 | 2025 | |
| Merck Sharp & Dohme LLC | $19.58 | 2024 | Vaxneuvance, Gardasil 9, Rotateq |
| Phathom Pharmaceuticals, INC. | $19.45 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $15.66 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.51 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Kuhl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.